Article Sidebar

Submitted
Jan 4, 2024
Accepted
Jan 26, 2024
Published
Sep 30, 2025
Download
PDF
Statistic
Read Counter : 2 Download : 1

Main Article Content

Abstract

Background: Hypertension followed by type 2 diabetes mellitus is a major risk factor for various cardiovascular diseases and is one of the chronic degenerative diseases Hence, it requires long-lasting treatment therapy and high costs. Based on this, hypertensive patients with DM type 2 need special attention in order to get effective hypertensive therapy at minimum cost. Cost-effectiveness analysis is an analytical method for making decisions on the best alternative to the therapy used. Objectives: To determine the most cost-effective hypertensive therapy in hypertensive patients with DM type 2 diabetes who underwent pharmacoeconomic hospitalization with a cost-effectiveness analysis approach. Methods: This type of study is descriptive observational with a retrospective data collection method from January 2021 - June 2023. The data taken was 31 medical records data and bill fees that met the inclusion criteria. Results: The description of drug use in hypertensive patients with DM type 2 diabetes at RSUD Soehadi Prijonegoro Sragen consists of monotherapy (19.35%) and combination (80.65%). The effectiveness of monotherapy was highest in patients receiving amlodipine therapy (12.42 mmHg), while the effectiveness of the combination was highest in patients taking adalat oros + candesartan + bisoprolol + furosemide + clonidine (22,38 mmHg). From the calculation of the ACER value, it was found that the most cost-effective drug was amlodipine, which had an ACER value of Rp. 289,962 in monotherapy and amlodipine + candesartan with an ACER value of Rp. 262,626. Conclusions: The most widely used hypertension therapy is combination therapy; the drug with the highest effectiveness is adalat oros + candesartan + bisoprolol + furosemide + clonidine and the drug with the highest cost-effectiveness is amlodipine monotherapy and the combination of amlodipine + candesartan.

Keywords

Cost-effectiveness analysis Hypertension therapy Type 2 diabetes mellitus

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

How to Cite
Jati, A. R. A., Sugihantoro, H., & Syahrir, A. (2025). Cost Effectiveness Analysis of Hypertensive Therapy in Hypertensive Patients with Type 2 of Diabetes Mellitus at RSUD Dr. Soehadi Prijonegoro Sragen: Analisis Efektivitas Biaya Terapi Hipertensi pada Pasien Hipertensi dengan Diabetes Melitus Tipe 2 di RSUD dr. Soehadi Prijonegoro Sragen. Jurnal Farmasi Galenika (Galenika Journal of Pharmacy) (e-Journal), 11(1), 34-48. https://doi.org/10.22487/j24428744.2025.v11.i1.16955

References

  1. Abraham, G., et al. (2022). Renoprotective role of amlodipine in patients with hypertensive chronic kidney disease. World Journal of Nephrology. Volume 11, No. 3, pp 86–95.
  2. Ahmad, A., dan Oparil, S. 2017. Hypertension in Women: Recent Advances and Lingering Questions. Hypertension. Volume 70, No 1, pp 19–26.
  3. Andayani. T.M. 2013. Farmakoekonomi: Prinsip dan Metodologi. Yogyakarta: Bursa Ilmu
  4. Ansa, D. A., Goenawi, L. R., dan Tjitrosantoso, H. M. 2021. Kajian Penggunaan Obat Antihipertensi pada Pasien Diabetes Melitus Tipe 2 di Instalasi Rawat Inap BLU RSUP Prof. Dr. R. D. Kandou Manado periode Januari-Desember 2010. Jurnal FMIPA UNSRAT Manado. pp 22–26.
  5. [BPS] Badan Pusat Statistik. 2018. Jumlah Kasus 10 Penyakit Terbanyak di Kota Batu, 2018. bps.go.id. (diakses pada tanggal 20 mei 2023).
  6. Bani, et al. 2022. The Prevalence of Hypertension and Its Progression among Patients with Type 2 Diabetes in Jordan. Annals of Medicine and Surgery. Volume 73, No. 103162, pp 1-4.
  7. Bakri, D. F. F., 2017. Analisis Efektivitas Biaya Terapi hipertensi pada Pasien Hipertensi Komplikasi Diabetes Melitus Tipe 2 Rawat Inap Peserta BPJS di RSUD Sukoharjo Tahun 2016 [skripsi]. Surakarta: Program Studi Farmasi Universitas Muhammadiyah Surakarta
  8. Decroli, E. 2019. Diabetes Mellitus Tipe 2. Padang: Pusat Penerbitan Bagian Ilmu Penyakit Dalam.
  9. DiPiro, J. T., et al. 2020. Pharmacotherapy: A Pathophysiology Approach, 10th Edition. New York: Mc-Graw Hill Medical.
  10. Fares, H., DiNicolantonio, J. J., O’Keefe, J. H., dan Lavie, C. J. 2016. Amlodipine in hypertension: A first-line Agent with Efficacy for Improving Blood Pressure and Patient Outcomes. Open Heart. Volume 3 No. 2, pp 1–7.
  11. Hauser J, M., Azzam, J, S., dan Kasi, A. 2022. Antiemetic Medications. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK532303/
  12. Hurst, C., Thinkhamrop, C., dan Tran, H.T. 2015. The Association between Hypertension Comorbidity and Microvascular Complications in Type 2 Diabetes Patients : A Nationwide Cross-Sectional Study in Thailand. Diabetes Metabolism Journal. Volume 39, No. 5, pp 395–404.
  13. Katzung, B, G., dan Trevor, G. J. 2015. Basic & Clinical Pharmacology Thirteenth Edition. San Fransisco: McGraw-Hill Education.
  14. [KEMENKES RI] Kemenkes RI. 2013. Pedoman Penerapan Kajian Farmakoekonomi. Jakarta; Kementrian Kesehatan RI.
  15. [KEMENKES RI] Kementrian Kesehatan RI. 2019. Hari Hipertensi Dunia 2019: “Know Your Number, Kendalikan Tekanan Darahmu dengan CERDIK. Diakses pada tanggal 8 juni 2023. https://p2ptm.kemkes.go.id/tag/hari-hipertensi-dunia-2019-know-your-number-kendalikan-tekanan-darahmu-dengan-cerdik
  16. [KEMENKES RI] Kementerian Kesehatan RI. 2018. Hasil Riset Kesehatan Dasar (Riskesdas) 2018. Jakarta: Badan Penelitian dan Pengembangan Kesehatan Kementerian RI.
  17. Patel, B. M., dan Mehta, A. A. 2013. Choice of Anti-Hypertensive Agents in Diabetic Subjects. Diabetes and Vascular Disease Research. Volume 10, No. 5, pp 385–396.
  18. Patel, H. et al s, K. A. 2020. Hypertension in older adults: Assessment, management, and challenges. Clinical Cardiology. Volume 43, No. 2, pp 99–107.
  19. [PERHI] Perhimpunan Dokter Hipertensi Indonesia. 2019. Konsensus Penatalaksanaan Hipertensi 2019. Jakarta: Indonesian Society Hipertensi Indonesia.
  20. Petrie, J. R., Tomas, J. G., dan Rhian M. T. 2018. Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. Canadian Journal of Cardiology. Volume 34, No 5, pp 575–84. doi: 10.1016/j.cjca.2017.12.005.
  21. Potalangi, S. S., dan Tirayoh. 2014. Penerapan Biaya Relevan Dalam Pengambilan Keputusan Membuat Sendiri Atau Membuat Produk Setengah Jadi Untuk Meningkatkan Laba Pada Cv. Tabea. Jurnal EMBA. Volume 2, No. 2, pp 1251–60.
  22. Rimoldi, S. F., Messerli, F. H., Chavez, P., Stefanini, G. G., dan Scherrer, U. 2015. Efficacy and Safety of Calcium Channel Blocker/Diuretics Combination Therapy in Hypertensive Patients: A Meta-Analysis. Journal of Clinical Hypertension. Volume 17, No. 3, pp 193–199.
  23. Rosyidah, K. A., Arina Z. P., Wahid S., and Bintari T. S. 2021. Reformasi Pelayanan Kesehatan Primer pada Puskemas Rawat. Indonesia Jurnal Farmasi. Volume 7, No. 1, pp 52–62.
  24. Sabrini, A. M., Febrianty, F., dan Shafira, N. N. A. 2022. Karakteristik Pasien DM Tipe 2 dengan Hipertensi Di Poliklinik Penyakit Dalam RSUD Raden Mattaher Jambi Tahun 2016-2019. Joms. Volume 2, No. 2, pp 72–80
  25. [WHO] World Helath Organization. 2023. Blood pressure/hypertension. Diakses pada tanggal 8 juni 2023. https://www.who.int/data/gho/indicator-metadata-registry/imr-details/3155
  26. [WHO] World Helath Organization. 2023. Hypertension. Diakses pada tanggal 8 juni 2023. https://www.who.int/news-room/fact-sheets/detail/hypertension
  27. [WHO] World Helath Organization. 2023. Noncommunicable disease. Diakses pada tanggal 8 juni 2023. https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases.